Impact of Right Atrial Appendage Ligation vs. Repair on Serum Atrial Natriuretic Peptide, Brain Natriuretic Peptide, and Atrial Fibrillation following Coronary Artery Bypass Grafting

What Was Tested

The paper reports a study of BNP (Nesiritide) and ANP (Atrial Natriuretic Peptide), published as a randomized controlled trial.

In this study, the researchers aimed to compare the levels of serum atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) with ligation and primary repair of right atrial appendage after venous decannulation procedure in isolated coronary artery bypass grafting (CABG) and their relationship with postoperative atrial fibrillation (POAF).

Who Took Part

The abstract describes 38 patients taking part.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

In this prospective randomized study, 38 patients who underwent isolated CABG in Haydarpasa Training Hospital between March 2015 and November 2015 were included.

Patients were divided into two groups whose atrial appendage were ligated (group A) or primary repaired (group B) after right atrial appendage decannulation.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got BNP (Nesiritide) and who got the comparison, which limits bias.

Both groups were evaluated in terms of perioperative serum ANP/BNP levels and POAF incidence.

ANP/BNP levels were measured by taking blood samples through the central venous catheter on the preoperative day and postoperative days 1 and 3.

What Was Measured

The subject headings attached to it are Atrial Fibrillation, Atrial Appendage, Natriuretic Peptide, Brain, Coronary Artery Bypass, Atrial Natriuretic Factor, Ligation and Postoperative Complications.

The authors tagged it with the keywords Atrial Fibrillation..

What This Means in Plain Language

The paper is a randomized study of BNP (Nesiritide) and ANP (Atrial Natriuretic Peptide) in 38 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Brazilian journal of cardiovascular surgery), a journal based in Brazil.

More context: the BNP (Nesiritide) compound page and the ANP (Atrial Natriuretic Peptide) compound page, all human trials.